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Redox State of Pentraxin 3 as a Novel
Biomarker for Resolution of Inflammation and
Survival in Sepsis*□S
Friederike Cuello‡§¶, Manu Shankar-Hari**, Ursula Mayr‡, Xiaoke Yin‡,
Melanie Marshall‡, Gonca Suna‡, Peter Willeit‡‡§§, Sarah R. Langley‡,
Tamani Jayawardhana‡, Tanja Zeller¶¶, Marius Terblanche, Ajay M. Shah‡,
and Manuel Mayr‡
In an endotoxaemic mouse model of sepsis, a tissue-
based proteomics approach for biomarker discovery
identified long pentraxin 3 (PTX3) as the lead candidate
for inflamed myocardium. When the redox-sensitive ol-
igomerization state of PTX3 was further investigated,
PTX3 accumulated as an octamer as a result of disul-
fide-bond formation in heart, kidney, and lung—com-
mon organ dysfunctions seen in patients with sepsis.
Oligomeric moieties of PTX3 were also detectable in
circulation. The oligomerization state of PTX3 was
quantified over the first 11 days in critically ill adult
patients with sepsis. On admission day, there was no
difference in the oligomerization state of PTX3 between
survivors and non-survivors. From day 2 onward, the
conversion of octameric to monomeric PTX3 was con-
sistently associated with a greater survival after 28 days
of follow-up. For example, by day 2 post-admission,
octameric PTX3 was barely detectable in survivors, but
it still constituted more than half of the total PTX3 in
non-survivors (p < 0.001). Monomeric PTX3 was in-
versely associated with cardiac damage markers NT-
proBNP and high-sensitivity troponin I and T. Relative to the
conventional measurements of total PTX3 or NT-proBNP, the
oligomerization of PTX3 was a superior predictor of disease
outcome. Molecular & Cellular Proteomics 13: 10.1074/
mcp.M114.039446, 2545–2557, 2014.
Severe sepsis is a common acute illness in intensive care
units (ICUs)1 and is associated with high mortality rates and
chronic morbidity. When it is associated with hypotension
(termed septic shock), the mortality rate is very high (50% to
80%). Cardiovascular dysfunction during sepsis is multifacto-
rial and often associated with minimal loss of myocardial
tissue, but with the release of myocardial-specific markers
such as troponins. A key unmet clinical need is the availability
of a biomarker that predicts myocardial dysfunction early,
monitors response to treatment, and thus identifies a cohort
of patients at higher risk of septic shock to aid in targeted
interventions and improve outcome (1).
In the present study, we used proteomics for biomarker
discovery. Over the past decade, the field of proteomics has
made impressive progress. Plasma and serum, however, are
the most complex proteomes of the human body (2), and less
abundant proteins tend to be missed in untargeted proteom-
ics analyses of body fluids (3). Thus, we pursued an alterna-
tive strategy: the application of proteomics to diseased tissue
(4), in which the potential biomarkers are less dilute and have
a less uncertain cellular origin (5–7). We employed a solubility-
based protein-subfractionation methodology to analyze in-
flammatory proteins that are retained with sepsis tissue. This
innovative proteomics approach shall reveal inflammatory mol-
ecules that reside and persist within inflamed tissue. We hy-
pothesized that proteins that accumulate in the susceptible
tissues are more likely to be biomarker candidates for organ
dysfunction than proteins that just circulate in plasma or serum.
We then validated our proteomics findings in the preclinical
model using samples from sepsis patients admitted to ICUs.
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EXPERIMENTAL PROCEDURES
Materials—Antibodies recognizing pentraxin 3 (PTX3) were from
Epitomics, Burlingame, CA (now Abcam, Cambridge, UK), -actinin
was from Sigma, cardiac myosin-binding protein C was a kind gift
from Prof. Mathias Gautel from King’s College London, telethonin was
from Santa Cruz Biotechnology, Dallas, TX, and GAPDH conjugated
to horseradish peroxidase (HRP) was from Abcam. All other chemi-
cals were from Calbiochem, Invitrogen, Sigma-Aldrich, or VWR Inter-
national, Lutterworth, Leicestershire, UK, unless otherwise stated.
Male C57BL/6J mice were obtained from B&K Universal Ltd, Grim-
ston, Aldbrough, Hull, UK.
Animal Models—All experiments were performed in accordance
with UK Home Office regulations, and the investigation conformed
with the Guide for the Care and Use of Laboratory Animals published
by the U.S. National Institutes of Health (NIH Publication No. 85–23,
revised 1996). The mouse model employed in this study was one of
moderate-severity endotoxemia and has been characterized in detail
previously (8, 9). In this model, there is significant hypotension with an
approximately 25% to 30% decrease in systolic blood pressure at 12
to 18 h after lipopolysaccharide (LPS) injection. This is associated
with significant cardiac dysfunction as assessed via in vivo volume
loading protocols (8) or in terms of ex vivo cardiac myocyte contrac-
tion (9). Mortality is 10% at this stage. C57/BL6 mice were injected
intraperitoneally with 9 mg/kg Escherichia coli bacterial LPS (serotype
0.11:B4, Sigma Aldrich, UK). Control animals received intraperitoneal
injections with an equivalent volume of saline. Mice were sacrificed 6
to 8 or 16 to 18 h after injection (9). Proteomics was performed 16 to
18 h post-injection, and immunoblot analysis was performed at both
an early (6 to 8 h) and a late time point (16 to 18 h).
Immunohistochemical Analysis—Tissue was post-fixed in 4%
formaldehyde, processed to paraffin blocks using an ASP300S de-
hydration machine (Leica, Wetzlar, Germany) and an EG1160 tissue-
embedding system (Leica), and cut into 4-m-thick slices. Sections
were stained using a Ventana Benchmark XT machine (Ventana,
Tuscon, AZ). Deparaffinized sections were incubated for 60 min in
CC1 solution (Ventana) for antigen retrieval. Primary antibodies were
diluted in 5% goat serum (Dianova, Hamburg, Germany), 45% Tris-
buffered saline, pH 7.6, and 0.1% Triton X-100 in antibody diluent
solution (Zytomed, Berlin, Germany). Sections were then incubated
with primary antibody against Iba1 (Wako Chemicals, Neuss, Ger-
many, 1:2000), Ly6G (eBiosciences, San Diego, CA, 1:2000), or PTX3
(TNFAIP5 polyclonal, HRP conjugated, 1:100) for 60 min. Histofine
Simple Stain MAX PO Universal immunoperoxidase polymer pur-
chased from Nichirei Biosciences (Wedel, Germany) was used as
secondary antibody. Detection of secondary antibodies was per-
formed with an Ultraview Universal DAB detection kit from Ventana.
Counterstaining was performed using Ventana’s hematoxylin solu-
tion. Sections were coverslipped using TissueTek glove mounting
medium (Sakura Finetek, Staufen, Germany) and dried in an incubator
at 60 °C.
Subfractionation of Mouse Hearts—Mouse heart homogenates
were subfractionated into Triton-soluble and Triton-insoluble frac-
tions. Briefly, 1% (v/v) Triton X-100 was added to the mouse heart
homogenates, which were then incubated for 15 min on a shaking
platform at 4 °C and centrifuged at 13,000g for 5 min (4 °C). The
Triton-soluble fraction was separated from the Triton-insoluble frac-
tion, and non-reducing Laemmli sample buffer was added.
Proteomics Analysis—The Triton-insoluble fractions from control
(n  4) and septic (n  4) groups were denatured in Laemmli buffer at
97 °C for 5 min. The proteins were separated by 5–20% gradient
Tris-glycine gel at 5 W for 45 min and then 30 W for 4.5 h. After
electrophoresis, gels were stained using the PlusOne Silver Staining
Kit (GE Healthcare). Silver staining was used for band staining to
avoid cross-contamination with fainter gel bands. All gel bands (n 
48 per sample) were excised in identical parallel positions across
lanes, and no empty gel pieces were left behind. Subsequently, all gel
bands were subjected to in-gel tryptic digestion using an Investigator
ProGest (Digilab, Marlborough, MA) robotic digestion system. Tryptic
peptides were separated on a nanoflow LC system (Dionex Ultimate
3000, Thermo Fisher Scientific) using reversed phase columns
(PepMap C18, 25 cm  75 m) and eluted with a 40-min gradient
(10% to 25% B in 35 min, 25% to 40% B in 5 min, 90% B in 10 min,
and 2% B in 20 min, where A was 2% acetonitrile, 0.1% formic acid
in HPLC H2O and B was 90% acetonitrile, 0.1% formic acid in HPLC
H2O). Sequentially eluted peptides were directly analyzed via tandem
mass spectrometry (LTQ Orbitrap XL, Thermo Fisher Scientific) using
full ion scan mode over the mass-to-charge (m/z) range of 450–1600.
Tandem MS (MS/MS) was performed on the top six ions using the
data-dependent mode with dynamic exclusion (10, 11). Peak lists
were generated using extract_msn_com.exe (version 5.0, Thermo
Fisher Scientific) and searched against the UniProt/Swiss-Prot mouse
database (version 2014_01, 16,656 protein entries) using Mascot
(version 2.3.01, Matrix Science, Boston, MA). The mass tolerance was
set at 30 ppm for the precursor ions and at 0.8 Da for fragment ions.
Carboxyamidomethylation of cysteine was used as a fixed modifica-
tion, and oxidation of methionine as a variable modification. Two
missed cleavages were allowed. Scaffold (version 4.3.0, Proteome
Software Inc., Portland, OR) was used to calculate the normalized
spectral counts and to validate peptide and protein identifications.
According to the default values in the Scaffold software, peptide
identifications were accepted if they could be established at greater
than 95% probability as specified by the Peptide Prophet algorithm.
Only tryptic peptides were included in the analysis. Protein identifi-
cations were accepted if they could be established at greater than
99% probability with at least two independent peptides.
Proteomic Differential Expression Analysis—Proteomic differential
expression was assessed using the normalized spectral abundance
factor power-law global error model (12). The normalized spectral
abundance factor was calculated for each protein detected. Spectral
count values of 0 were replaced by an empirically derived fractional
value. The value was calculated to be the smallest value between 0
and 1, which provided the best fit to a normal distribution, as deter-
mined by a Shapiro–Wilks test. The normalized spectral abundance
factor values were fit to a power-law global error model; differentially
expressed proteins were then identified through a signal-to-noise
(STN) test statistic. Proteins were kept for further analysis if spectra
were detected in at least two samples per group or if spectra were
detected in all samples of one group and were absent in all samples
of the other group. The false discovery rate was estimated by com-
paring the signal-to-noise statistic to an empirically derived null dis-
tribution using the resampling procedure described by Pavelka et al.
and implemented in the plgem R package (13).
Preparation of Tissue Homogenates—Control and septic hearts or
other tissues (aorta, kidney, spleen, liver, lung, muscle, brain) were
excised and washed briefly in ice-cold Tyrode’s solution (pH 7.4)
containing in 130 mM NaCl, 5.4 mM KCl, 1.4 mM MgCl2, 0.4 mM
NaH2PO4, and 4.2 mM HEPES to remove blood. The tissue was
snap-frozen in liquid nitrogen before homogenization using a motor-
driven blade “on ice” in a Tris-based homogenization buffer (pH 7.4)
containing 100 mM Tris/HCl, 100 mM EDTA, 100 mM maleimide, and
protease inhibitors (Roche) at a ratio of 100 mg/ml (10%). Laemmli
sample buffer with 10% -mercaptoethanol (reducing) or 100 mM
maleimide (non-reducing) was added to the tissue homogenates, and
samples were passed through a narrow-gauge needle to shear DNA.
Preparation of Mouse Plasma Samples—Whole mouse blood from
control or LPS-treated mice was collected, and 2 mM EDTA was
added. The samples were centrifuged for 15 min at 2000g at 4 °C to
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deplete cells. Non-reducing Laemmli sample buffer was added to the
resulting plasma supernatant.
SDS-PAGE and Immunoblot Analysis—Protein samples from tis-
sue homogenates, fractionated homogenates, or plasma samples in
reducing or non-reducing Laemmli sample buffer were separated via
7.5%, 10%, or 15% SDS-PAGE, transferred to polyvinylidene difluo-
ride membranes, and subjected to immunoblotting. Primary antibod-
ies were detected by donkey anti-rabbit or sheep anti-mouse sec-
ondary antibodies linked to HRP (GE Healthcare). Specific protein
bands were detected via enhanced chemiluminescence (GE Health-
care) and quantified on a calibrated densitometer (GS-800, Bio-Rad)
using Quantity One® one-dimensional analysis software (v. 4.5.1).
Fluorescence Immunohistochemical Staining—Mouse hearts were
prepared as described above. For antigen retrieval, deparaffinized
sections were boiled for 60 min in 10 mM citrate buffer (10 mM sodium
citrate, 0.05% Tween-20, pH 6.0) using a steamer. Afterward, sec-
tions were blocked for 60 min in PBS containing donkey serum (1.2
mg/ml; Dianova) and then with 1% Sudan black in 70% ethanol for 20
min in order to decrease autofluorescence of the tissue. After rigorous
washing, sections were incubated with anti-PTX3 (1:100; Abcam,
Cambridge, UK) primary antibody overnight at 4 °C. Sections were
then washed again, and secondary donkey anti-rabbit IgG Alexa 633
labeled antibody (1:200; Invitrogen, Darmstadt, Germany) was ap-
plied for 60 min. Nuclei were counterstained by 0.4 g/ml 46-di-
amidino-2-phenylindole (DAPI) (Roche, Munich, Germany) in PBS for
10 min, and slides were mounted in Fluoromount G (Biozol, Munich,
Germany). Images were taken on a fluorescence light microscope
equipped with a digital camera (Axio Imager M2, Zeiss, Jena,
Germany).
Study Population—An observational cohort study was performed
in an 88-bed university hospital general medical-surgical ICU. The
study protocol received ethical approval from an institutional review
board (REC reference 12/LO/0326); written informed consent was
obtained either from the patient, if mentally competent, or from the
next of kin, and the consent procedure was completed with retro-
spective consent. The clinical management of the patient was at the
discretion of the attending physicians. The investigators analyzing
samples were blinded to patients’ outcomes while conducting the
experiments. Consecutive patients meeting the definition for severe
sepsis within the first 12 h following ICU admission between May and
October 2011 were included. Severe sepsis was defined as evidence
of two or more systemic inflammatory response syndrome criteria,
with proven or suspected infection and at least one organ system
dysfunction (cardiovascular, respiratory, renal, hematological, or met-
abolic) (14). Organ function was classified and categorized using the
sequential organ failure assessment score. Exclusion criteria included
patients younger than 18 years, those with congenital hypogam-
maglobulinemia, known protein-losing enteropathies, nephrotic syn-
drome, neoplastic or proliferative hematological diseases, those hav-
ing received intravenous immunoglobulins in the past 3 months, those
receiving high-dose steroid therapy, those having other ongoing im-
mune dysfunction as defined by the APACHE II co-morbidities, on-
going blood loss (defined by a blood transfusion requirement of 2
units/24-h period), and retroviral disease. Blood samples for mea-
surements were obtained daily from day 0 (ICU admission) until day 6
and at day 11. Whole blood from septic patients was collected at the
indicated time points; the blood was allowed to clot by being left
undisturbed at room temperature for 15 to 30 min. The clot was
removed by centrifugation at 2000g for 10 min at 4 °C. Following
centrifugation, the serum was immediately transferred into a clean
polypropylene tube and stored at80 °C. For immunoblotting, serum
samples were incubated with Blue Sepharose® CL-6B (50 l per 200
l of serum) at 4 °C for 1 h on a shaking platform to deplete from
serum albumin. Samples were centrifuged at 1000g for 1 min at 4 °C
to remove Blue Sepharose® CL-6B beads, non-reducing Laemmli
sample buffer was added, and equal volumes of depleted samples
were analyzed via Western immunoblot analysis.
Immunoassays—NT-proBNP and high-sensitivity troponin T were
determined via the electrochemiluminescence sandwich immunoas-
say ECLIA on an Elecsys 2010 system (Roche Diagnostics, Germany)
in serum samples according to the manufacturers’ recommendations.
The assay range for NT-proBNP was 5 to 35,000 pg/ml, the assay
range for high-sensitivity troponin T was 3 to 10,000 pg/ml. High-
sensitivity troponin I was determined by means of cardiac troponin
assay (ARCHITECT STAT highly sensitive Troponin I immunoassay on
an ARCHITECT i2000SR, Abbott Diagnostics). The established limit of
detection for the assay ranges from 0.8 to 1.9 with amedian of 1.5 pg/ml
and an assay range of 0–50,000 pg/ml. Human Pentraxin 3/TSG-14was
measured in 28 participants, including all non-surivivors, with a Quan-
tikine ELISA Kit from R&D Systems, Minneapolis, MN.
Statistics—Monomeric, tetrameric, and octameric PTX3 levels in
patients admitted to the ICU were not normally distributed. We there-
fore used the median and interquartile range to summarize their
distributions and used the Wilcoxon rank-sum test to formally test for
differences between participants who survived the 28-day follow-up
period and those who did not. Analogous methods were used for the
biomarkers NT-proBNP, high-sensitivity troponin T, and high-sensi-
tivity troponin I. Analyses were performed using Stata release 12.1
(StataCorp, College Station, TX). Statistical tests were two-sided and
used a significance level of p  0.05.
RESULTS
Biomarker Discovery in a Preclincial Model—For our pro-
teomic investigation, we chose the mouse model of endotox-
emia to identify biomarker candidates. As organs susceptible
to sepsis-induced dysfunction, hearts were isolated from con-
trol or septic mice 16 to 18 h after the injection of vehicle
saline solution or LPS (9 mg/kg intraperitoneal) (9). Before
proteomics, all tissue specimens were examined histologi-
cally. Macrophage and neutrophil infiltration was detected via
immunostaining within 6 to 8 h after LPS injection. Represent-
ative images are shown in Fig. 1A. Hearts were obtained from
control and LPS-treated mice (n  4 per group). To enable a
better characterization of inflammatory proteins retained
within the cardiac tissue, we used a solubility-based protein
subfractionation methodology based on 1% Triton. The Tri-
ton-insoluble protein extracts were separated via SDS-PAGE
(supplemental Fig. S1), subjected to in-gel tryptic digestion,
and analyzed via LC-MS/MS using a high-mass-accuracy ion
trap (LTQ-Orbitrap XL, Thermo Fisher Scientific). The entire
MS/MS dataset has been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset
identifier PXD001020 and DOI 10.6019/PXD001020 (www.
ebi.ac.uk/pride/). Only proteins passing stringent identifica-
tion criteria are listed in supplemental Table S1 (n  1910).
The identified peptides corresponding to these protein
identifications are given in supplemental Table S2. According
to the Gene Ontology Annotation database, 66 non-redundant
proteins were secreted proteins in the Triton-insoluble frac-
tion. Differences in relative protein abundance between con-
trol and LPS-treated hearts were estimated using normalized
spectral counts (Table I). No outliers were removed. Details
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FIG. 1. Proteomics in a preclinical model of sepsis. A, hematoxylin and eosin (H&E) staining of hearts from control C57Bl6 and
LPS-treated mice. Immunostaining for the macrophage marker ionized calcium binding adaptor molecule 1 (Iba-1) and the granulocyte
marker Ly6G. B, differential expression in the proteomic analysis. Note the pronounced up-regulation of pentraxin 3 (PTX3) in the
Triton-insoluble fraction of LPS-treated hearts. C, comparative quantification for PTX3 via mass spectrometry; equal expression of
-actinin-1 (ACTN1 MOUSE) and cardiac myosin-binding protein C (MYPC3 MOUSE). D, representative immunoblots of the Triton-
insoluble fraction performed on four hearts per group. Probing for -actinin, cardiac myosin-binding protein C (cMyBP-C), and Coomassie
staining assured equal protein loading.
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TABLE I
Extracellular/secreted proteins identified via proteomics in the Triton-insoluble fraction of cardiac tissue
Protein name Swiss-Protaccession
Controla
(mean spectra 	 S.D.)
LPSa
(mean spectra 	 S.D.)
Log fold
change
False
discovery
rate
Pentraxin-related protein PTX3 PTX3_MOUSE 0 	 0 10 	 4 19.67 0.003b
Galectin-1 LEG1_MOUSE 8 	 3 22 	 4 1.36 0.016b
Thioredoxin THIO_MOUSE 4 	 5 9 	 5 1.02 0.049b
von Willebrand factor A domain-containing protein 1 VWA1_MOUSE 6 	 1 2 	 2 1.71 0.058b
Versican CSPG2_MOUSE 8 	 16 1 	 1 3.14 0.062b
Inter--trypsin inhibitor heavy chain 4 ITIH4_MOUSE 3 	 3 9 	 7 1.51 0.078b
Vitronectin VTNC_MOUSE 4 	 3 8 	 7 1.15 0.094b
Complement C3 CO3_MOUSE 2 	 2 6 	 4 1.64 0.109
Mimecan MIME_MOUSE 5 	 2 2 	 2 1.12 0.112
Prolargin PRELP_MOUSE 18 	 12 29 	 10 0.66 0.117
Antithrombin-III ANT3_MOUSE 2 	 1 4 	 3 1.12 0.135
Calmodulin CALM_MOUSE 3 	 4 5 	 5 0.73 0.14
Reticulon-3 RTN3_MOUSE 4 	 2 2 	 2 1.38 0.14
Complement C1q tumor necrosis factor related
protein 9
C1QT9_MOUSE 4 	 4 2 	 2 0.98 0.161
Dermatopontin DERM_MOUSE 23 	 6 16 	 4 0.49 0.169
Collagen -1 (I) CO1A1_MOUSE 6 	 7 3 	 4 1.09 0.194
Laminin subunit -2 LAMB2_MOUSE 54 	 8 35 	 14 0.60 0.211
Collagen -6 (VI) CO6A6_MOUSE 2 	 2 5 	 2 1.09 0.238
Dystroglycan DAG1_MOUSE 5 	 1 3 	 2 0.84 0.248
Uncharacterized aarF domain containing protein
kinase 1
ADCK1_MOUSE 1 	 1 2 	 2 0.91 0.256
Annexin A2 ANXA2_MOUSE 8 	 2 12 	 3 0.47 0.257
Laminin subunit -5 LAMA5_MOUSE 4 	 2 1 	 2 1.31 0.264
Collagen -1 (XV) COFA1_MOUSE 15 	 2 10 	 3 0.66 0.265
Apolipoprotein A-I APOA1_MOUSE 6 	 3 4 	 3 0.49 0.295
Vinculin VINC_MOUSE 131 	 52 106 	 8 0.30 0.309
Translationally controlled tumor protein TCTP_MOUSE 3 	 4 2 	 3 0.48 0.323
Decorin PGS2_MOUSE 25 	 10 30 	 6 0.28 0.346
Inter- trypsin inhibitor heavy chain 1 ITIH1_MOUSE 6 	 2 9 	 3 0.48 0.356
Periostin POSTN_MOUSE 11 	 6 15 	 6 0.40 0.367
Fibrinogen  chain FIBG_MOUSE 6 	 3 8 	 4 0.39 0.371
Cadherin-13 CAD13_MOUSE 19 	 5 15 	 3 0.36 0.382
Clusterin CLUS_MOUSE 3 	 1 4 	 4 0.44 0.396
Papilin PPN_MOUSE 16 	 7 12 	 4 0.43 0.396
Perlecan PGBM_MOUSE 10 	 4 7 	 3 0.56 0.439
Ceruloplasmin CERU_MOUSE 3 	 1 4 	 3 0.45 0.452
Peroxidasin homolog PXDN_MOUSE 5 	 4 7 	 4 0.44 0.452
Glutathione peroxidase 3 GPX3_MOUSE 5 	 5 6 	 2 0.27 0.456
Protein-glutamine -glutamyltransferase 2 TGM2_MOUSE 27 	 2 31 	 11 0.23 0.466
Collagen -1 (VI) CO6A1_MOUSE 84 	 13 73 	 22 0.20 0.481
Galectin-9 LEG9-MOUSE 4 	 1 3 	 3 0.34 0.482
EMILIN-1 EMIL1_MOUSE 15 	 5 12 	 4 0.31 0.492
EGF-containing fibulin-like extracellular matrix
protein 1
FBLN3_MOUSE 4 	 2 3 	 2 0.37 0.492
Coatomer subunit  COPA_MOUSE 2 	 2 2 	 3 0.49 0.497
Talin-1 TLN1_MOUSE 10 	 3 7 	 6 0.38 0.537
Nidogen-1 NID1_MOUSE 88 	 16 78 	 8 0.17 0.543
Filamin-A FLNA_MOUSE 8 	 7 6 	 2 0.39 0.546
Apolipoprotein O APOO_MOUSE 13 	 6 12 	 6 0.17 0.558
Dehydrogenase/reductase SDR family member 7C DRS7C_MOUSE 21 	 5 18 	 5 0.17 0.558
Gelsolin GELS_MOUSE 5 	 2 4 	 2 0.29 0.565
Fibronectin FINC_MOUSE 2 	 1 3 	 2 0.41 0.574
Apolipoprotein O-like APOOL_MOUSE 23 	 8 25 	 11 0.13 0.588
von Willebrand factor A domain-containing protein 8 VWA8_MOUSE 14 	 3 12 	 9 0.25 0.608
Asporin ASPN_MOUSE 5 	 5 5 	 3 0.15 0.687
Collagen -2 (VI) CO6A2_MOUSE 47 	 4 44 	 10 0.10 0.708
Laminin subunit -1 LAMC1_MOUSE 35 	 12 32 	 4 0.12 0.721
Protein disulfide-isomerase PDIA1_MOUSE 2 	 2 3 	 1 0.16 0.721
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can be found in “Experimental Procedures.” Long PTX3 was
returned as the most pronounced change (Fig. 1B). PTX3 is an
acute-phase glycoprotein secreted in response to proinflam-
matory cytokines (15). The quantitative difference according
to the proteomics data (Fig. 1C) was validated by immuno-
blotting. Immunblots confirmed a marked increase of PTX3 in
the Triton-insoluble cardiac extracts under endotoxemic con-
ditions (Fig. 1D). Equal protein loading was demonstrated by
immunoblotting for the sarcomeric proteins -actinin and car-
diac myosin-binding protein C, and by Coomassie staining.
Redox-dependent Oligomerization of PTX3—Oligomeriza-
tion of PTX3 into tetrameric and octameric complexes via
interprotein disulfide-bond formation through adjacent cys-
teine residues in PTX3 monomer subunits was described as a
prerequisite for its biological activity and binding to constitu-
ents of the extracellular matrix (16). To further investigate the
enrichment of PTX3 in septic hearts, the Triton-soluble and
Triton-insoluble fractions were compared under reducing and
non-reducing conditions 6 to 8 h post–LPS injection (n  3
per group). The effectiveness of subfractionation by 1% Triton
was confirmed by immunoblotting for selected markers of
different cardiomyocyte compartments, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (cytosolic) and tele-
thonin (particulate/myofilament) (Fig. 2A). Under reducing
conditions, PTX3 was clearly detectable as a 45-kDa moiety in
sepsis hearts (Fig. 2A, upper panel). N-linked glycosylation
accounts for a 5-kDa shift of PTX3 with a predicted molecular
mass for the reduced protein of 40 kDa (17). Immunoblot
analysis performed under non-denaturing conditions revealed
that PTX3 formed high-molecular-weight complexes resulting
in the formation of tetramers (180 kDa) and octamers (360
kDa) (Fig. 2A, lower panel) in response to oxidant exposure.
Although both the tetramer and the octamer were present in
the Triton-soluble fraction, only the octamer was detectable in
the Triton-insoluble fraction of septic hearts. Next, we tested
different tissue homogenates. Interestingly, there was a pre-
ponderance of the oxidized versus the reduced form of PTX3,
with oxidized PTX3 accumulating in the heart, aorta, kidney,
and lung—organs that are known to be susceptible to septic
complications (Fig. 2B, upper and lower panels). Less oxi-
dized PTX3 was retained in the spleen and liver. This is
consistent with previous reports that LPS induces PTX3 ex-
pression in vivo in heart and lung but not in liver (18, 19). The
high-molecular-weight PTX3 moieties were converted to
monomers under reducing conditions. In contrast, no PTX3
protein was detectable in tissue homogenates of control mice.
Notably, the immunoblots presented in Fig. 2C highlight
bands consistent with the expected molecular weights of
tetrameric and octameric moieties of PTX3 in plasma of septic
mice. PTX3 can be expressed by a variety of cells in response
to LPS and inflammatory cytokines (20, 21). Positive immu-
nostaining for PTX3 in the heart was predominantly observed
in the vicinity of smaller vessels (Fig. 3) at sites of leukocyte
and macrophage infiltration (supplemental Fig. S2). Besides
PTX3, known first- and second-degree interaction partners of
PTX3 were identified in the proteomics screen (Fig. 4).
Circulating PTX3 in Sepsis Patients—PTX3 is barely detect-
able in the plasma of healthy individuals (2 ng/ml), but its
concentration can increase to up to 200 ng/ml in sepsis,
depending on the severity of the disease (22). High PTX3
plasma levels are correlated with severity of infection in pa-
tients with sepsis or septic shock (23–25). Based on our
findings in the preclinical model, we quantified octameric,
tetrameric, and monomeric PTX3 levels in critically ill patients
with sepsis but without established acute organ failure (AOF)
referred to ICU Outreach Teams (n  31). Their clinical char-
acteristics are shown in Table II. Samples were taken in a
longitudinal manner at eight different time points: on the day
of admission to ICU (day 0), at days 1 through 6, and at day
11. Immunoblot analysis was performed under non-reducing
conditions in a total of 204 samples (Fig. 5A). Next, we tested
to see whether the levels of the different oligomeric PTX3
moieties could be used to distinguish survivors from non-
survivors. On day 0, there was no difference in octameric,
TABLE I—continued
Protein name Swiss-Protaccession
Controla
(mean spectra 	 S.D.)
LPSa
(mean spectra 	 S.D.)
Log fold
change
False
discovery
rate
Transforming growth factor--induced protein ig-h3 BGH3_MOUSE 9 	 3 10 	 1 0.12 0.721
Nidogen-2 NID2_MOUSe 10 	 7 10 	 3 0.13 0.74
Lumican LUM_MOUSE 26 	 8 28 	 9 0.06 0.764
Tubulointerstitial nephritis antigen-like TINAL_MOUSE 10 	 4 11 	 4 0.08 0.767
Fibulin-5 FBLN5_MOUSE 2 	 3 3 	 2 0.11 0.779
Laminin subunit -1 LAMB1_MOUSE 22 	 8 23 	 6 0.08 0.789
Plasminogen PLMN_MOUSE 2 	 2 1 	 0 0.10 0.842
Fibromodulin FMOD_MOUSE 2 	 3 2 	 3 0.06 0.845
Fibrinogen  chain FIBB_MOUSE 6 	 4 6 	 2 0.02 0.882
Matrin-3 MATR3_MOUSE 8 	 3 8 	 3 0.02 0.913
Laminin subunit -2 LAMA2_MOUSE 46 	 10 46 	 7 0.00 0.924
a Four biological samples analyzed per group (n  4).
b Indicates proteins with a false discovery rate  0.1.
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FIG. 2. Redox state of PTX3 in endotoxemia. A, the different oxidation states of PTX3 in the heart (octamer, tetramer, and monomer) were
visualized in the Triton-soluble (sol) and -insoluble (insol) fractions under reducing (upper panel) or non-reducing conditions (bottom panel).
Representative immunoblots from three mouse hearts per group were probed for PTX3, telethonin (marker of the insoluble myofilament-containing
compartment), and GAPDH (marker of the soluble cytosol-containing compartment). B, tissue samples from heart, aorta, kidney, spleen, liver, lung,
muscle, and brain were subjected to immunoblot analysis under non-reducing (upper panel) or reducing (bottom panel) gel conditions and probed
for PTX3. C, plasma samples from control C57Bl6 and LPS-treated mice were depleted of albumin and analyzed for PTX3 protein content and
oxidation state using immunoblot analysis under non-reducing conditions. The representative immunoblots display the results of four mice per group.
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tetrameric, and monomeric PTX3 levels between survivors
and non-survivors. Over the time course of 11 days, however,
the transformation of octameric to monomeric PTX3 was as-
sociated with greater survival during 28-day follow-up (Fig.
5B). As early as day 2 post-admission, PTX3 oligomerization
predicted adverse clinical outcome: Octameric PTX3 was
barely detectable in survivors but constituted more than 50%
of total PTX3 in non-survivors (p 0.001; Fig. 5C). In contrast,
FIG. 3. Localization of PTX3. Immu-
nofluorescence staining for PTX3.
Perivascular localization of PTX3 (green)
in hearts from LPS-treated mice. Nuclear
counterstaining with DAPI (blue).
FIG. 4. Protein interactions of PTX3. Protein interactions of PTX3, from Innate DB, are shown with PTX3 in red. The dark gray nodes are
the first and second-degree interaction proteins from PTX3; the light gray nodes are proteins that form a complex that interacts with PTX3.
Abbreviations are given as Gene ID (Human). The large nodes in blue are proteins identified by proteomics (supplemental Table S1).
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monomeric PTX3 constituted 90% of total PTX3 in survivors
but only 20% in non-survivors (p  0.013). There was no
significant difference in tetrameric PTX3 between survivors
and non-survivors.
Comparison to Established Biomarkers—Secreted PTX3
can bind to pathogens to induce classical complement acti-
vation (20). Notably, monomer levels of PTX3 were inversely
correlated to complement C3a (rs  0.455, n  24, p 
0.014), as well as the cardiac and stress markers high-sensi-
tivity troponin I (rs  0.565, n  28, p  0.001), high-
sensitivity troponin T (rs  0.358, n  28, p  0.067), and
N-terminal pro-B-type natriuretic peptide (rs  0.352, n 
28, NT-proBNP, p 0.066) (supplemental Fig. S3A), suggest-
ing that the absence of oligomerization is associated with less
complement activation and less cardiac tissue damage. Pa-
tients with the maximum cardiovascular sequential organ failure
assessment score (n  19) at day 1 post-admission to ICU had
on average 4-fold higher oligomerized PTX3 levels than patients
with a lower cardiovascular sequential organ failure assessment
score (n  12) (oligomerized PTX3, density in arbitrary units,
mean	 S.E.: 1.38	 0.40 versus 0.31	 0.18, p 0.022). Unlike
oligomerized PTX3 moieties, the cardiac damage markers were
not significantly correlated with the survival of patients (supple-
mental Fig. S3B). Octameric and monomeric PTX3 levels at day
2 predicted the 28-day survival better than a model containing
total PTX3 as measured by conventional ELISA (AUROC: 0.918
versus 0.626; p value: 0.045; Fig. 6A) or NT-proBNP (AUROC:
0.918 versus 0.687; p value: 0.023; Fig. 6B), a marker for left
ventricular dysfunction that is frequently increased in severe
sepsis (26). Although octameric to monomeric PTX3 was supe-
rior to total PTX3 and NT-proBNP, this single biomarker did not
outperform the APACHE II score related risk prediction (AUROC
0.918 versus 0.803, p  0.25), which includes clinical variables
and organ dysfunction biochemistry and accounts for co-mor-
bidities (27).
DISCUSSION
Our study provides proof-of-principle data that the oligomer-
ization state of PTX3 may represent a superior prognostic
marker relative to total PTX3 in adult critically ill patients with
severe sepsis. This distinction between the oligomerization
state of PTX3 and conventional measurements of total PTX3
is important, as the oligomerization state might better mirror
the changes in the underlying complex interactions between
immune-inflammatory insults and redox stress in sepsis.
Furthermore, key strengths of our study are the bridging of
proteomics discovery to bedside validation and the direct
comparison to established biomarkers, which directly ad-
dresses the main criticisms often highlighted in proteomics
biomarker research.
Role of PTX3—Together with C-reactive protein and serum
amyloid P component, PTX3 belongs to the family of pentrax-
ins. Although C-reactive protein is used as a marker of sys-
temic inflammation, its prognostic value in sepsis is poor (28).
PTX3 plays an important role in regulating the innate immune
response by contributing to opsonization (29). In mice, over-
expression of PTX3 confers resistance to the lethal effects of
LPS (30). LPS injection elicits the secretion of several cyto-
kines, including interleukin-1 and tumor necrosis factor , two
potent inducers of PTX3. Unlike the classical pentraxins C-
reactive protein and serum amyloid P component, PTX3 does
not bind phosphoethanolamine or phosphocholine, but it
does bind collagen-like C1q, the first component of the clas-
sical pathway of complement activation. Its capacity to bind
C1q is mediated by the pentraxin domain and requires mul-
timer formation (17). Thus, PTX3 oligomers may reflect activity
better than total PTX3 as measured by ELISA. As expected on
the basis of C1q binding, high PTX3 may cause the consump-
tion of C4 and of the total complement hemolytic activity in
serum (17).
TABLE II
Clinical characteristics of sepsis patients
Variablea
Entire study
cohort (n  31)
28-day survivors
(n  23)
28-day non-survivors
(n  8)
p valueb
Age (years) 67.4 	 11.9 66.0 	 12.2 71.0 	 12.8 0.29
Male:female, n (%) 19:12 (61.3%:38.3%) 15:8 (65.3%:34.7%) 4:4 (50.0%:50.0%) 0.45
APACHE II score 20.6 	 6.0 19.3 	 6.1 24.4 	 3.7 0.03
Medical:surgical, n 26:5 (83.8%:16.1%) 18:5 (78.3%:21.7%) 8 (100%) 0.20
WCC ( 109/l) 13.5 (1.3, 49.1) 11.3 (1.3, 25.8) 17.8 (11.8, 49.1) 0.04
CRP (mg/l) 130 (8, 429) 143 (8, 429) 115 (29, 148) 0.13
CVS SOFA score 4 (0, 4) 4 (0, 4) 4 (0, 4) 0.47
Renal SOFA score 1 (0, 4) 1 (0, 4) 0 (0, 4) 0.50
t-SOFA score 8 (4, 12) 8 (2, 14) 8 (3, 13) 0.98
RRT, n 5 4 1 0.77
ICU LOS (days) 9.9 	 5.7 9.5 	 6.3 11 	 3.5 0.23
Hospital LOS (days) 23 (4, 216) 30 (7, 216) 11 (4, 18) 0.001
APACHE, Acute Physiology and Chronic Health Evaluation II; WCC, white cell count; CRP, C-reactive protein; CVS SOFA, cardiovascular
sequential organ failure assessment; t-SOFA, total sequential organ failure assessment; RRT, renal replacement therapy; LOS, length of stay.
a Values presented are unadjusted means 	 S.D., range (min, max), or percentages.
b p values were calculated via t test (continuous variables) or the 2 test (categorical variables).
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PTX3 and Inflammation—Resolution of inflammation is not
a passive process and requires stop signals (31). In severe
sepsis, an uncontrolled inflammatory response to infection
causes damage to and subsequent failure of organs such as
the lungs, heart, and kidneys. The underlying mechanisms of
AOF are not well understood, and no effective mediator-
targeted therapies for established AOF are available (32).
Medical care of patients combines prompt treatment with
antibiotics and supportive care and often requires artificial
organ support provided in an ICU. Numerous studies have
tested novel therapeutics attempting to block key steps in the
inflammatory processes associated with AOF. However, de-
spite over 200 sepsis randomized controlled trials since 1992,
no effective therapies exist. Most interventions have failed
FIG. 5. Association of PTX3 oligomerization with patient survival. A, representative immunoblots of the development of the PTX3
oligomerization state with time after admission in a non-surviving sepsis patient (upper panel) and in a surviving sepsis patient (bottom panel).
N-numbers corresponding to patient death or dropout are given for each time point. B, serum samples from 31 septic patients after admission
to ICU (day 0) over a time course of 11 days were analyzed for PTX3 levels after albumin depletion. Monomeric, tetrameric, and octameric PTX3
levels were quantified for each patient and time point using Western immunoblot analysis performed under non-reducing conditions. Asterisks
(*) denote statistically significant differences between patients who died and those who survived during the follow-up time (28 days); p  0.05.
C, distribution of PTX3 oligomer levels on day 2 post-admission to ICU compared between survivors and non-survivors.
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when tested in rigorous trials (33). Previous anti-inflammatory
interventions mainly targeted circulating inflammatory cells or
inflammatory mediators (i.e. by dialysis). The observed reten-
tion of oxidized PTX3 in the Triton-insoluble fraction and the
inverse correlation of circulating monomeric PTX3 with car-
diac damage markers support the concept that inflammation
and tissue damage may be perpetuated locally. Thus, in ad-
dition to targeting circulating mediators of inflammation, re-
solving the inflammation within the tissues might be a prom-
ising strategy in the prevention of AOF.
Clinical Significance—AOF in sepsis is common and is as-
sociated with high mortality, short-term morbidity, and signif-
icant chronic illness. Many biomarkers have been identified,
but they lack specificity or sensitivity. Our tissue-based pro-
teomics approach (34, 35) led to the novel observation that
the oligomerization state of PTX3 could be a better prognostic
biomarker in sepsis than total PTX3 as measured by conven-
tional ELISA. Mechanistically, PTX3 oxidation may be linked
to innate immunity and increased oxidative stress during in-
flammation (i.e. by the respiratory burst during neutrophil
extracellular trap formation). Although levels of octameric
PTX3 on admission day were not different between survivors
and non-survivors, a dynamic change in the oligomerization
state of PTX3 within the first 2 days might assist in identifying
treatment response, or lack thereof, in patients with progres-
sive illness or persistent organ dysfunction. A single bio-
marker, however, is unlikely to outperform the APACHE score,
which consists of 12 variables (age, rectal temperature, mean
arterial pressure, pH arterial, heart rate, respiratory rate, se-
rum sodium, serum potassium, creatinine, hematocrit, leuko-
cyte count, and the Glasgow Coma Scale).
Strengths and Limitations—ELISA technology is widely
used in clinical diagnostics to detect total protein levels. In
this work, we have demonstrated that the oligomerization
state of circulating PTX3 might provide an important advan-
tage over total PTX3 or cardiac damage markers in determin-
ing treatment response. Further studies in larger cohorts are
required in order to confirm whether the oligomerization state
of PTX3 is a superior surrogate end point for therapeutic
interventions. As mediator molecules in the responses of the
innate immune system, PTX3 multimers might be not only an
indicator of but also a contributor to the deleterious host
responses in sepsis. Whether this is a mechanism for the
prolongation of tissue inflammation and progression to AOF
awaits clarification in future studies (36).
CONCLUSIONS
An estimated 200,000 U.S. ICU patients die every year. Our
findings suggest that the transformation of octameric to mo-
nomeric PTX3 in survivors might be a surrogate end point for
the inflection point at which oxidative stress subsides and
inflammation turns into resolution/repair. If sepsis patients at
FIG. 6. Comparison of the discriminatory power of octameric and monomeric PTX3 and other markers. A, receiver operating
characteristic curves of PTX3 measurements compared with total PTX3. Octameric and monomeric PTX3 levels at day 2 predicted the 28-day
survival better than a model containing total PTX3 as measured by conventional ELISA (28 observations, area under the receiver operating
characteristic curve (AUROC): 0.918 versus 0.626; p value: 0.045). B, receiver operating characteristic curves of PTX3 measurements
compared with NT-proBNP and the clinical APACHE II score. Octameric and monomeric PTX3 levels at day 2 predicted the 28-day survival
better than a model containing NT-proBNP (28 observations, AUROC: 0.918 versus 0.687; p value: 0.023) but failed to significantly outperform
the APACHE II score in this patient cohort (28 observations, AUROC: 0.918 versus 0.803, p  0.25).
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risk of developing AOF could be identified early, this novel
biomarker could help to “personalize” critical care medicine.
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